Multicohort assessment of plasma metabolomic measurements across the atherosclerosis continuum
This multicohort study identifies a robust metabolomic signature across the atherosclerosis continuum, revealing specific plasma metabolites associated with subclinical coronary atherosclerosis, myocardial infarction, and plaque vulnerability that could enhance risk stratification and understanding of disease mechanisms.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human heart is a tireless pump, but the pipes that feed it can slowly clog over decades. This clogging, known as atherosclerosis, is the buildup of fatty deposits and scar tissue inside the arteries. It is a silent process that often goes unnoticed until a sudden blockage causes a heart attack or stroke. For a long time, doctors have relied on traditional warning signs like high blood pressure, smoking, and cholesterol levels to guess who is at risk. However, these signs do not tell the whole story of how the disease starts or why it strikes some people and not others. To understand the early stages of this clogging, scientists have begun looking at the body's chemical soup. Inside our blood, thousands of tiny molecules called metabolites float around, acting as the end products of the body's daily chemical reactions. These molecules are like the exhaust fumes of a car engine; by studying them, researchers hope to see what is happening inside the engine long before the car breaks down.
A team of researchers set out to map these chemical exhaust fumes against the actual state of the heart's arteries. They focused on a large group of nearly 8,200 people from Sweden who had no history of heart disease. Using advanced imaging scans, the team looked inside the participants' hearts to see if there were any early signs of plaque buildup, even if the arteries were not yet blocked. They then measured the levels of over 1,100 different metabolites in the blood of these same people. By comparing the chemical profiles with the images of the arteries, they searched for specific molecules that appeared more often in people with early signs of clogging. The goal was to find a chemical fingerprint that could reveal the disease before it became dangerous.
The study identified twelve specific metabolites that were strongly linked to the presence of early arterial clogging, even after the researchers accounted for known risk factors like age, smoking, and blood pressure. Among these were phosphate and malate, a substance involved in how the body produces energy. The researchers also found three different types of sphingomyelins, which are a kind of fat found in cell membranes. Interestingly, the relationship between these fats and heart disease was the opposite of what might be expected. While high levels of phosphate and malate were associated with more clogging, higher levels of these specific sphingomyelins were linked to less clogging. The team also identified a mysterious molecule, labeled X-25790, which appeared to be a type of nucleoside, a building block of genetic material, though its exact identity remains unconfirmed.
To ensure these findings were not just a fluke, the researchers tested them in other groups of people representing different stages of heart disease. They looked at a group of people who were about to have a heart attack within six months and found that the same chemicals were present in their blood. In another group of people who had already survived a heart attack, they examined the arteries that were not the cause of the attack but were still diseased. They found that the levels of the protective sphingomyelins were lower in people who had more dangerous, unstable plaque in their arteries. This consistency across different groups suggests that these twelve molecules are not just random markers but are deeply involved in the process of the disease from its earliest, silent stages to its most severe, life-threatening forms.
The researchers also explored how these chemicals relate to other health factors. They found that the protective sphingomyelins were linked to higher levels of "good" cholesterol and lower levels of "bad" cholesterol. This suggests that these fats might be part of how the body packages and transports cholesterol. The study did not prove that these chemicals cause the disease or that changing their levels would cure it. Instead, it provides a clear list of suspects that warrant further investigation. By identifying these specific molecules, the study offers a new way to look at heart disease, moving beyond simple risk factors to understand the complex chemical machinery driving the clogging of our arteries. This work lays the groundwork for future tests that could one day detect heart trouble years before a patient ever feels a symptom.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.